AndrewEugeneHendifarMD

Oncology • West Hollywood, CA

Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology, Complementary and Integrative

Director, Pancreas Oncology

Join to view full profile

Dr. Hendifar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hendifar's full profile

Already have an account?

Office
8700 Beverly Blvd
West Hollywood, CA 90048
Phone+1 310-933-4470

Fax+1 310-933-4174

Summary

Dr. Andrew Hendifar is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, Ronald Reagan UCLA Medical Center, Providence Saint John's Health Center, and Cedars-Sinai Medical Center. He received his medical degree from Tulane University School of Medicine and has been in practice 14 years. He specializes in cancer genetics/cancer risk assessment, gastrointestinal cancer, hematologic oncology, and complementary and integrative and is experienced in pancreatic cancer, amyloidosis, hematologic oncology, neuroendocrine tumors, and myelodysplasia.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2007 - 2009
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2003 - 2006
Tulane University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2004 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Start of enrollment: 2013 Jun 10
COMPLETED
PHASE4
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer Start of enrollment: 2013 Oct 02
Completed
Phase 1
Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study Start of enrollment: 2013 Jan 01
Completed
Early Phase 1
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain Start of enrollment: 2020 Oct 01
Withdrawn
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency Start of enrollment: 2020 Dec 17
Recruiting
Phase 2
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31
ACTIVE_NOT_RECRUITING
PHASE3
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Start of enrollment: 2020 Nov 16
Terminated
Phase 2
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Start of enrollment: 2021 Jul 28
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model.
Philip J Chang, Andrew E Hendifar, Gillian Gresham, An Ngo-Huang, Paul E Oberstein
Cancers. 2025-02-13
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Aurelien Marabelle, David M O'Malley, Andrew E Hendifar, Paolo A Ascierto, Daniel Motola-Kuba
Nature Cancer. 2025-02-01
Chemopreventive strategies for sporadic colorectal cancer: a narrative review.
Savanna Monson, Pin-Jung Chen, Alexandra Gangi, Kevin Waters, Sandrine Billet
Translational Gastroenterology and Hepatology. 2025-01-01

Lectures

A prospective trial of elemental enteral feeding in patients with pancreatic cancer cachexia (PANCAX-1).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020